Published on October 7, 2009 at 5:44 AM
Helix BioPharma Corp. (TSX, FSE: HBP / OTCQX: HXBPF) today announced progress updates for its ongoing Topical Interferon Alpha-2b and L-DOS47 product development programs following pre-investigational new drug ("pre-IND") meetings with the U.S. Food and Drug Administration ("FDA").
Helix requested the pre-IND meetings in order to confirm its plans for future investigational new drug ("IND") filings with the FDA. The meeting on Topical Interferon Alpha-2b was designed to confirm the data requirements needed, beyond the completed Phase II cervical dysplasia study to proceed to Phase II/III clinical testing in the U.S. for this indication. The pre-IND meeting on L-DOS47 was designed to receive guidance from the FDA on requirements that must be met by Helix before requesting approval to begin a Phase I study in the U.S.
"We are very pleased with the outcomes of both pre-IND meetings with the FDA," said John Docherty, president and chief operating officer of Helix BioPharma. "Our discussions confirmed our expectations of what is necessary to proceed with both clinical programs and we now have a clearly identified path to progress to those clinical investigations."
SOURCE Helix BioPharma Corp.
1d460e7d-5747-4e9e-aa15-9a83447d6df3|0|.0
Posted in: Pharmaceutical News
Tags: Antibody, Cancer, Cell, Cervical Dysplasia, Chemotherapy, Dysplasia, Exercise, Lung Cancer, Non-Small Cell Lung Cancer, Pharmacology, Radiation Therapy, Small Cell Lung Cancer, Toxicology